Immunomodulation With Eltrombopag in ITP (iROM2)
Primary Immune Thrombocytopenia (ITP)
About this trial
This is an interventional treatment trial for Primary Immune Thrombocytopenia (ITP) focused on measuring eltrombopag, thrombopoietin receptor agonist (TPO-RA), ITP in young and midlife adults
Eligibility Criteria
Inclusion Criteria:
- Informed consent as documented by signature
- Newly diagnosed primary ITP according to the definition of Rodeghiero et al. and a risk of platelet count of <30x109/l or risk of severe bleeding
- First-line therapy maximum for 1 week prior to enrolment
- Bleeding severity and quality of life are neither an inclusion nor an exclusion criterion.
Exclusion Criteria:
- Patients previously treated for ITP more than 7 days prior to enrolment (e.g. Steroid, intravenous immunoglobulin (IVIG), platelet infusion)
- Patients treated with second-line drugs prior to enrolment
- Life-threatening bleeding (and inability to sign informed consent)
- Secondary ITP
- Positive family history for ITP
- Presence or history of autoimmune disease as judged by the investigator
- Hepatosplenomegaly in the clinical examination
- Relevant hepatic disease as judged by the investigator
- Presence or history of thromboembolic disease
- Patients with splenectomy
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Lack of safe double contraception
- Any vaccination 2 weeks prior start of the study
- Immunsuppressive and antiplatelet drugs
- Known or suspected non-compliance, drug or alcohol abuse
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, incompetence to judge
- Participation in another study with investigational drug within the 30 days preceding and during the present study
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Sites / Locations
- Aarau Cantonal Hospital, Division of HematologyRecruiting
- University Children's Hospital Basel (UKBB)Recruiting
- University Hospital Basel, Division of HematologyRecruiting
- University Hospital Bern, Division of HematologyRecruiting
- Liestal Cantonal Hospital, Division of HematologyRecruiting
- Lucerne Cantonal Hospital, Division of HematologyRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Experimental
Standard Arm
Study Arm
HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1: No planed further treatment. = standard therapy (without eltrombopag)
HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2: The subjects in the experimental arm will be treated with eltrombopag: Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows.